Bridging computer science and biomedicine

E. Ray Dorsey
Editor-in-Chief
E. Ray Dorsey, University of Rochester, Rochester, N.Y., USA

Section Editor “Network of Digital Evidence (NODE)”
A. Atreja, Icahn School of Medicine at Mount Sinai, New York, N.Y., USA

Advisory Board
M. Frasier, The Michael J. Fox Foundation for Parkinson’s Research, New York, N.Y., USA
E. Hafen, ETH, Zurich, Switzerland
J.D. Hixson, University of California San Francisco, San Francisco, Calif., USA
D. Karlin, Pfizer, Cambridge, Mass., USA
J. Kvedar, Mass General Hospital, Boston, Mass., USA
M. Little, Aston University, Birmingham, UK
K.D. Mandl, Harvard University, Boston, Mass., USA
W.J. Marks Jr., Verily Life Sciences, San Francisco, Calif., USA
M. Rebhan, Novartis, Basel, Switzerland
S. Scherer, Novartis, East Hanover, N.J., USA
E. Schwede, University of Basel, Basel, Switzerland
J. Wilbanks, Sage Bionetworks, Seattle, Wash., USA

Digital biomarkers are defined as objective, quantifiable physiological and behavioral data that are collected and measured by means of digital devices such as portables, wearables, implantables or digestibles. The data collected is typically used to explain, influence and/or predict health-related outcomes. Digital biomarkers also represent an opportunity to capture clinically meaningful, objective data.

Multidisciplinary by design, this innovative open access journal bridges the disciplines of computer science, engineering, biomedicine, regulatory science and informatics. The editorial board includes leaders from academia, life sciences, technology and government, thus reflecting the broad scope of the journal. Papers are published within 60 days of submission and the inclusion of videos or other visual materials is supported. Moreover, Digital Biomarkers provides and supports access to data, algorithms and app-repositories linked to the articles published in the journal.

Digital Biomarkers
Category: Clinical Research
Fields of Interest: Bioinformatics, Digital Medicine
2017: Volume 1
e-ISSN 2504–110X

www.digitalbiomarkers.info
Submission Information

Six reasons to submit your paper
• Peer review
• 60 days from submission to publication
• Open Access
• Currently no author processing charges
• Videos and other visuals included at no charge
• Have your data, algorithms and apps included in the associated repository

Guidelines for Authors – Excerpt
Mission of the journal
To foster the emerging field of digital biomarkers to enhance health by:
• Publishing and disseminating leading research and ideas in the field
• Creating a multi-disciplinary community that spans industries
• Developing novel ways to advance the field

Types of articles accepted
• Original Papers
• Reviews
• Short Communications
• Technical Notes

Peer-Review Policy
Our aim is to provide authors with timely and constructive feedback regarding their submitted manuscript. The Editor-in-Chief and the international editorial board ensure a thorough and fair peer-review and the highest scientific publishing standards.

Conditions
All manuscripts are subject to editorial review. Copyright of manuscripts is retained by the authors. Authors grant S. Karger AG, Basel, an exclusive unlimited license to publish the article under a Creative Commons license and identify S. Karger AG as the original publisher. By submitting an article for publication, the authors agree to its publication under the applicable Creative Commons license and the terms and conditions of the Publisher’s Licensing Agreement. It is the authors’ responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications. Signed permission forms from the copyright holders and original authors for all previously published tables or figures must be provided.

More information: www.karger.com/dib_guidelines

www.digitalbiomarkers.info